EP3331880B3 - Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques - Google Patents

Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques Download PDF

Info

Publication number
EP3331880B3
EP3331880B3 EP16831959.8A EP16831959A EP3331880B3 EP 3331880 B3 EP3331880 B3 EP 3331880B3 EP 16831959 A EP16831959 A EP 16831959A EP 3331880 B3 EP3331880 B3 EP 3331880B3
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
mmol
pyridin
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16831959.8A
Other languages
German (de)
English (en)
Other versions
EP3331880A1 (fr
EP3331880A4 (fr
EP3331880B1 (fr
Inventor
Shudong Wang
Solomon Tadesse ZELEKE
Mingfeng YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aucentra Therapeutics Pty Ltd
Original Assignee
Aucentra Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903106A external-priority patent/AU2015903106A0/en
Application filed by Aucentra Therapeutics Pty Ltd filed Critical Aucentra Therapeutics Pty Ltd
Priority to EP21196611.4A priority Critical patent/EP3957637B1/fr
Publication of EP3331880A1 publication Critical patent/EP3331880A1/fr
Publication of EP3331880A4 publication Critical patent/EP3331880A4/fr
Application granted granted Critical
Publication of EP3331880B1 publication Critical patent/EP3331880B1/fr
Publication of EP3331880B3 publication Critical patent/EP3331880B3/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to a novel class of inhibitors of protein kinasesuseful in the treatment of proliferative cell diseases and conditions including cancers.
  • CDKs Cyclin-dependent kinases
  • CDKs are a type of protein kinase. They are known to be associated with various cyclin subunits, playing pivotal roles in the regulation of a variety of important regulatory pathways in cells, including cell-cycle control, apoptosis, neuronal physiology, differentiation and transcription.
  • CDKs There are more than 20 CDKs which may be classified into two major groups, reflecting their functions; namely, the cell cycle regulator CDKs and the transcription regulator CDKs.
  • the class of the cell cycle regulator CDKs includes CDK1, CDK2, CDK3, CDK4 and CDK6, and they function with their cyclin partners (eg cyclin A, B, D1, D2, D3, E and F) to regulate promotion of the cell cycle.
  • the class of the transcription regulator CDKs includes CDK7, CDK8, CDK9 and CDK11, which work together with cyclin C, H, K, L1, L2, T1 and T2 and tend to play roles in transcriptional regulation. Given the functions of these two CDK classes, it is perhaps not surprising that CDKs have been implicated in cell proliferation diseases and conditions, particularly cancer. Cell proliferation is a result of the direct or indirect deregulation of the cell division cycle and the CDKs play a critical role in the regulation of the various phases of this cycle. Therefore, inhibitors of CDKs and their associated cyclins are considered to be useful targets for cancer therapy.
  • Certain pyrimidine-based compounds have been previously investigated for use in treating proliferative cell diseases and conditions including cancers, for example, 4-thiazol-2-pyridinylamino-pyrimidines and 5-substituted-4-thiazol-pyrimidines (see International patent publications WO 2005/012298 and WO2013/156780 , respectively). These compounds inhibit multiple protein kinases, particularly CDKs, including CDK1/cyclin B, CDK2/cyclin E, CDK2/cyclin A, CDK4/cyclin D1, CDK7/cyclin H and CDK9/cyclin T1.
  • CDKs particularly CDKs, including CDK1/cyclin B, CDK2/cyclin E, CDK2/cyclin A, CDK4/cyclin D1, CDK7/cyclin H and CDK9/cyclin T1.
  • the present applicant has now identified a new class of thiazole-pyrimidine compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. While not wishing to be bound by theory, it is considered that these novel compounds are capable of inhibiting cell proliferation by inhibiting the activity of CDK4 and/or CDK6.
  • the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt or solvate thereof, for treating cancer or another proliferative cell disease or condition wherein the proliferative cell disease or condition to be treated is selected from those characterised by over-expression of CDK4 and/or CDK6.
  • the present invention provides a pharmaceutical composition or medicament comprising a compound as defined in the first aspect and a pharmaceutically acceptable carrier, diluent and/or excipient.
  • the present applicant has now identified a new class of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives suitable for use in the prevention and/or treatment of proliferative cell diseases and conditions including cancers, which possess desirable biological activity (eg the compounds may inhibit cell proliferation by inhibiting the activity of CDK4 and /or CDK6).
  • the present invention provides a compound of formula II shown below: wherein:
  • the compounds of formula II may preferably comprise at least one water solubilising group R 10 , R 11 or R 12 . That is, in such embodiments, the compound is as defined above in paragraph [0012] with the proviso that said compound comprises at least one of said R 10 , R 11 and R 12 groups.
  • solubilising group(s) the compounds possess desirable biological activity (eg by inhibiting the activity of CDK4 and/or CDK6).
  • the presence of at least one water solubilising group may enhance in vivo absorption and oral bioavailability.
  • the compounds of formula II have been found to possess anti-proliferative activity and are therefore considered to be of use in the treatment of proliferative cell diseases and conditions such as cancer, leukaemia, lymphoma and other diseases and conditions associated with uncontrolled cell proliferation (or, in other words, requires control of the cell cycle) such as, for example, some cardiovascular diseases or conditions such as restenosis and cardiomyopathy, some auto-immune diseases such as glomerulonephritis and rheumatoid arthritis, dermatological conditions such as psoriasis, and fungal or parasitic disorders.
  • an anti-proliferative effect within the scope of the present invention may be demonstrated by the ability to inhibit cell proliferation in an in vitro whole cell assay.
  • the compounds of formula II may inhibit any of the steps or stages in the cell cycle, for example, formation of the nuclear envelope, exitfrom the quiescent phase of the cell cycle (G0), G1 progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2 progression, activation of mitotic or meioticfunctions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, and cytokinesis functions.
  • the compounds of formula II may influence certain gene functions such as chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways.
  • the present invention provides the use of a compound as defined in the first aspect or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating cancer or another proliferative cell disease or condition.
  • the present invention provides a pharmaceutical composition or medicament comprising a compound as defined in the first aspect and a pharmaceutically acceptable carrier, diluent and/or excipient.
  • the term “treating” includes prophylaxis as well as the alleviation of established symptoms of a condition.
  • the act of "treating" a disease or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the disease or condition developing in a subject afflicted with or predisposed to the disease or condition; (2) inhibiting the disease or condition (ie arresting, reducing or delaying the development of the disease or condition or a relapse thereof (in case of a maintenance treatment) or at least one clinical or subclinical symptom thereof; and (3) relieving or attenuating the disease or condition (ie causing regression of the disease or condition or at least one of its clinical or subclinical symptoms).
  • alkyl includes both straight chain and branched alkyl groups having from 1 to 8 carbon atoms (eg methyl, ethyl propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl etc).
  • aryl refers to a substituted (mono- or poly-) or unsubstituted monoaromatic or polyaromatic group, wherein said polyaromatic group may be fused or unfused.
  • the term therefore includes groups having from 6 to 10 carbon atoms (eg phenyl, naphthyl etc). It is also to be understood that the term “aryl” is synonymous with the term “aromatic”.
  • aralkyl is used as a conjunction of the terms alkyl and aryl as defined above.
  • alicyclic refers to a cyclic aliphatic group.
  • aliphatic takes its normal meaning in the art and includes non-aromatic groups such as alkanes, alkenes and alkynes and substituted derivatives thereof.
  • halogen refers to fluoro, chloro, bromo and iodo.
  • heterocyclic refers to a saturated or unsaturated cyclic group comprising one or more heteroatoms in the ring.
  • derivative includes any chemical modification of an entity. Illustrative of such chemical modifications is the replacement of hydrogen by a halogen group, an alkyl group, an acyl group or an amino group.
  • the phrase "manufacture of a medicament” includes the use of one or more of the compounds of formula II directly as the medicament or in any stage of the manufacture of a medicament comprising one or more of the compounds of formula II.
  • Some of the compounds of formula II may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates and mixtures thereof, are encompassed within the scope of the present invention.
  • the isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods known to those skilled in the art.
  • pharmaceutically acceptable salt refers to salts that retain the desired biological activity of the compounds of formula I, and include pharmaceutically acceptable acid addition salts and base addition salts.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric and phosphoric acid.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic and arylsulfonic. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995 .
  • Prodrug means a compound that undergoes conversion to a compound of formula II within a biological system, usually by metabolic means (eg by hydrolysis, reduction or oxidation).
  • metabolic means eg by hydrolysis, reduction or oxidation.
  • an ester prodrug of a compound of formula I containing a hydroxyl group may be convertible by hydrolysis in vivo to the compound of formula I.
  • Suitable esters of the compounds of formula I containing a hydroxyl group may be, for example, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-P-hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
  • an ester prodrug of a compound of formula I containing a carboxy group may be convertible by hydrolysis in vivo to the compound of formula I.
  • ester prodrugs include those described by Leinweber FJ, Drug Metab Rev 18:379-439 (1987 ).
  • an acyl prodrug of a compound of formula I containing an amino group may be convertible by hydrolysis in vivo to the compound of formula I. Examples of prodrugs for these and other functional groups, including amines, are provided in Prodrugs: challenges and rewards, Valentino J Stella (ed), Springer, 2007 .
  • therapeutically effective amount is an amount sufficient to effect beneficial or desired clinical results.
  • a therapeutically effective amount can be administered in one or more administrations.
  • a therapeutically effective amount is sufficient for treating a disease or condition or otherwise to palliate, ameliorate, stabilise, reverse, slow or delay the progression of a disease or condition such as, for example, cancer or another proliferative cell disease or condition.
  • a therapeutically effective amount of a compound of formula II, or a pharmaceutically acceptable salt, solvate or prodrug thereof may comprise between about 0.1 and about 250 mg/kg body weight per day, more preferably between about 0.1 and about 100 mg/kg body weight per day and, still more preferably between about 0.1 and about 25 mg/kg body weight per day.
  • the therapeutically effective amount may vary and depend upon a variety of factors including the activity of the particular compound (or salt or solvate thereof), the metabolic stability and length of action of the particular compound (or salt or solvate thereof), the age, body weight, sex, health, route and time of administration, rate of excretion of the particular compound (or salt or solvatethereof), and the severity of, for example, the cancer or other proliferative cell disease or condition to be treated.
  • the compounds of formula II, and pharmaceutically acceptable salts and solvatesthereof are capable of inhibiting protein kinases, especially CDKs and may show higher selectivity (to inhibit) CDK4 and/or CDK6 over other protein kinases.
  • CDK4 and CDK6 promote cancer cell proliferation.
  • the compounds of formula II, and pharmaceutically acceptable salts and solvates thereof, which are believed to inhibit CDK4 and/or CDK6, have utility in both in vitro and in vivo applications (eg in vitro cell-based assays) and as the basis of a therapeutic method of treating cancer or another proliferative cell disease or condition in a subject.
  • the compounds of formula II bear a thiazole group attached to the pyrimidine ring through one of the ring carbon atoms (particularly, the carbon at position 4).
  • the compounds of formula II may bear at least one water solubilising group (eg provided by R 10 , R 11 and/or R 12 ).
  • water solubilising group will be well understood by those skilled in the art as referring to any polar functional group which either ionises or is capable of forming hydrogen bonds with water molecules to increase the water solubility of the compound (ie relative to the water solubility of the corresponding compound lacking the water solubilising group). Examples of suitable water solubilising groups and methods and considerations for their introduction are described in, for example, Fundamentals of Medicinal Chemistry by Gareth Thomas (publisher: John Wiley & Sons ).
  • R 10 and R 11 are independently selected from water solubilising groups of the group consisting of:
  • R 12 is independently selected from the group of water solubilising groups consisting of: mono-, di- and poly-hydroxylated alicyclic groups, di- or poly-hydroxylated aliphatic or aryl groups, N-, O- and/or S-containing heterocyclic groups substituted with one or more hydroxyl or amino groups, aliphatic and aryl groups comprising one or more carboxamide, sulfoxide, sulfone or sulfonamide groups, and halogenated alkylcarbonyl groups, and COOH, SO 3 H, OSO 3 H, PO 3 H 2 and OPO 3 H 2 , except when R 5 and/or R 6 is R 12 , in which case R 12 is selected from the group of water solubilising groups consisting of: mono-, di- and poly-hydroxylated alicyclic groups, di- or poly-hydroxylated aliphatic or aryl groups, N-, O- and/or S-containing heterocyclic groups substituted with one or
  • R 1 is H, alkyl (eg a C 1-6 alkyl or, preferably, a C 1-3 alkyl such as methyl, ethyl and C(CH 3 ) 2 ), aryl, NH-alkyl (eg a NH-C 1-6 alkyl such as NH(C 5 H 9 ) (ie NH-cyclopentyl) or, preferably, a NH-C 1-3 alkyl such as NH-CH 3 ), N(alkyl) 2 (eg a N(C 1-6 alkyl) 2 such as N(C 5 H 9 ) 2 or a N(C 1-3 alkyl) 2 such as N(CH 3 ) 2 ), NH-aryl, N-(alkyl)(aryl), or R 12 .
  • R 1 is R 12 , preferably R 12 is a mono-, di- or poly-hydroxylated alicyclic group, or an N-, O- and/or S-containing heterocycl
  • R 2 is a C 1-3 alkyl such as methyl and ethyl.
  • R 3 is H, alkyl (eg a C 1-6 alkyl or, preferably, a C 1-3 alkyl such as methyl or ethyl), CN, or halogen (preferably F).
  • alkyl eg a C 1-6 alkyl or, preferably, a C 1-3 alkyl such as methyl or ethyl
  • CN or halogen (preferably F).
  • R 4 is H, O-alkyl (preferably, a C 1-6 alkoxy or, more preferably, a C 1-3 alkoxy such as methoxy or ethoxy) or halogen (preferably F).
  • At least one of R 5 and R 6 , but preferably R 5 is R 12 wherein R 12 is preferably an N-, O-and/or S-containing heterocyclic group substituted with one or more hydroxyl, amino or alkoxy (eg -COCH 3 ) group.
  • R 12 is preferably an N-, O-and/or S-containing heterocyclic group substituted with one or more hydroxyl, amino or alkoxy (eg -COCH 3 ) group.
  • the heteroatom(s) is/are N.
  • R 12 is preferably selected from the following:
  • R 12 substituents shown in the preceding paragraph [0044] may further comprise an alkyl bridge (eg a -CH 2 - or -CH 2 CH 2 - bridge) to the carbon atom at position 4/5 of the pyridine/phenyl ring.
  • an alkyl bridge eg a -CH 2 - or -CH 2 CH 2 - bridge
  • R 5 is R 12
  • R 6 is preferably H.
  • R 5 is preferably H.
  • R 7 is H.
  • R 5 is R 12 and R 4 , R 6 and R 7 are each independently selected from H, alkyl (eg a C 1-6 alkyl or, preferably, a C 1-3 alkyl), aryl, alicyclic, heterocyclic, halogen, NO 2 , CN, CF 3 , OH, O-alkyl (eg a C 1-6 alkoxy or, more preferably, a C 1-3 alkoxy such as methoxy or ethoxy), NH 2 , NH-alkyl (eg a NH-C 1-6 alkyl such as NH(C 5 H 9 ) or, preferably, a NH-C 1-3 alkyl such as NH-CH 3 ) and N-(alkyl) 2 (eg a N(C 1-6 alkyl) 2 such as N(C 5 H 9 ) 2 or a N(C 1-3 alkyl) 2 such as N(CH 3 ) 2 ).
  • alkyl eg a C
  • R 5 is R 12
  • R 1 is alkyl (eg a C 1-6 alkyl such as cyclopentyl or a C 1-3 alkyl such as methyl and ethyl), NH(alkyl) (eg a NH-C 1-6 alkyl or, preferably, a NH-C 1-3 alkyl), N(alkyl) 2 (eg a N(C 1-6 alkyl) 2 such as N(C 5 H 9 ) 2 or a N(C 1-3 alkyl) 2 such as N(CH 3 ) 2 ), NH(aryl), O-alkyl (eg a C 1-6 alkoxy or, more preferably, a C 1-3 alkoxy), and NH 2 , and R 4 , R 6 and R 7 are each independently selected from H, alkyl (eg a C 1-6 alkyl such as cyclopentyl or a C 1-3 alkyl), halogen, CN, CF 3
  • R 5 is R 12
  • R 1 is alkyl (eg a C 1-6 alkyl such as cyclopentyl or a C 1-3 alkyl such as methyl and ethyl), NH(alkyl) (eg a NH-C 1-6 alkyl or, preferably, a NH-C 1-3 alkyl), N(alkyl) 2 (eg a N(C 1-6 alkyl) 2 or, more preferably, a N(C 1-3 alkyl) 2 ), NH(aryl), O-alkyl (eg a C 1-6 alkoxy or, more preferably, a C 1-3 alkoxy), and NH 2 and R 4 , R 6 and R 7 are each independently selected from H, alkyl (eg a C 1-6 alkyl such as cyclopentyl or a C 1-3 alkyl), halogen, CN, CF 3 , O-alkyl (eg a C 1-6 alkoxy
  • the compounds of the present invention exhibit anti-proliferative activity in human cell lines, as measured by a standard cytotoxicity assay.
  • the compound exhibits an IC 50 value of less than 5 ⁇ M, even more preferably less than 1 ⁇ M as measured by the cell viability (MTT proliferation) assay described in Example 2 hereinafter. More preferably still, the compound exhibits an IC 50 value of less than 0.5 ⁇ M.
  • the compounds of the present invention inhibit one or more protein kinases, as measured by any standard assay well known to those skilled in the art.
  • the compound exhibits an IC 50 value of less than 1 ⁇ M or less than 0.5 ⁇ M as measured by the kinase assay described in Example 2 hereinafter, more preferably still less than 0.1 ⁇ M.
  • Table 1 Chemical structure of selected compounds of the present invention No. Structure Name Mass 1.
  • 1-(4-(6-((4-(2-(isopropylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl) amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one 452.6 58.
  • the compounds may be administered in combination with one or more additional agent(s) for the treatment of cancer or another proliferative disease or condition.
  • the compounds may be used in combination with other anti-cancer agents in order to inhibit more than one cancer signalling pathway simultaneously so as to make cancer cells more susceptible to anti-cancer therapies (eg treatments with other anti-cancer agents, chemotherapy, radiotherapy or a combination thereof).
  • the compounds of formula II may be used in combination with one or more of the following categories of anti-cancer agents:
  • a compound of the present invention and the other anti-cancer agent can be administered in the same pharmaceutical composition or in separate pharmaceutical compositions. If administered in separate pharmaceutical compositions, the compound and the other anti-cancer agent may be administered simultaneously or sequentially in any order (eg within seconds or minutes or even hours (eg 2 to 48 hours)).
  • the present invention is typically applied to the treatment of cancer or another proliferative cell disease or condition in a human subject.
  • the subject may also be selected from, for example, livestock animals (eg cows, horses, pigs, sheep and goats), companion animals (eg dogs and cats) and exotic animals (eg non-human primates, tigers, elephants etc).
  • Cancers and other proliferative cell diseases and conditions that may be treated in accordance with the present invention include biliary tract cancer, brain cancer (including glioblastomas and medulloblastomas), breast cancer, cervical cancer; choriocarcinoma, colonic cancer, endometrial cancer, oesophageal cancer, gastric cancer, haematological neoplasms (including acute lymphocytic leukemia (ALL)), chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML), acute myeloid leukaemia (AML), multiple myeloma, AIDS-associated leukemias and adult T-cell leukemia lymphoma, intraepithelial neoplasms (including Bowen's disease and Paget's disease), liver cancer, lung cancer, lymphomas (including Hodgkin's disease and lymphocytic lymphomas), neuroblastomas, oral cancer (including squamous cell carcinoma), ovarian
  • the compounds of the present invention are used to treat cancers characterised by over-expression of CDK4 and/or cyclin D including, for example, lung cancer ( Wu et al., J Transl Med 9:38 (2011 )), breast cancer ( An et al., Am J Pathol 154(1): 113-118 (1999 )), cancers of the central nervous system (CNS) and colorectal cancer ( Ikeda et al., Jap J Clin Med 54(4): 1054-1059 (1996 )).
  • lung cancer Wu et al., J Transl Med 9:38 (2011 )
  • breast cancer An et al., Am J Pathol 154(1): 113-118 (1999 )
  • cancers of the central nervous system (CNS) and colorectal cancer Ikeda et al., Jap J Clin Med 54(4): 1054-1059 (1996 )).
  • CDK4 and/or cyclin D over-expression may be determined by, for example, assessing the amount of mRNA encoding CDK4 and/or cyclin D in a suitable sample using any of the techniques well known to those skilled in the art (eg quantitative amplification techniques such as qPCR).
  • the compounds of the present invention are used to treat cancers characterised by over-expression of CDK6 and/or cyclin D including, for example, T-cell acute lymphoblastic leukemia (ALL), colorectal cancer and medullablastoma (reviewed in Tadesse et al., Cell Cycle. 14(20):3220-30, 2015 ).
  • CDK6 and/or cyclin D over-expression may be determined by, for example, assessing the amount of mRNA encoding CDK6 and/or cyclin D in a suitable sample using any of the techniques well known to those skilled in the art (eg quantitative amplification techniques such as qPCR).
  • the compounds of the present invention may be formulated into a pharmaceutical composition with a pharmaceutically acceptable carrier, diluent and/or excipient.
  • suitable carriers and diluents are well known to those skilled in the art, and are described in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 1995 .
  • suitable excipients for the various different forms of pharmaceutical compositions described herein may be found in the Handbook of Pharmaceutical Excipients, 2nd Edition, (1994), Edited by A Wade and PJ Weller .
  • suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like.
  • suitable diluents include ethanol, glycerol and water. The choice of carrier, diluent and/or excipient may be made with regard to the intended route of administration and standard pharmaceutical practice.
  • a pharmaceutical composition comprising a compound of the present invention may further comprise any suitable binders, lubricants, suspending agents, coating agents and solubilising agents.
  • suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol.
  • suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Preservatives, stabilising agents, dyes and even flavouring agents may be provided in the pharmaceutical composition.
  • preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Anti-oxidants and suspending agents may be also used.
  • a pharmaceutical composition comprising a compound of the present invention may be adapted for oral, rectal, vaginal, parenteral, intramuscular, intraperitoneal, intraarterial, intrathecal, intrabronchial, subcutaneous, intradermal, intravenous, nasal, buccal or sublingual routes of administration.
  • oral administration particular use may be made of compressed tablets, pills, tablets, gellules, drops, and capsules.
  • a pharmaceutical composition may comprise solutions or emulsions which may be injected intravenously, intraarterially, intrathecally, subcutaneously, intradermally, intraperitoneally or intramuscularly, and which are prepared from sterile or sterilisable solutions.
  • a pharmaceutical composition comprising a compound of the present invention may also be in form of suppositories, pessaries, suspensions, emulsions, lotions, ointments, creams, gels, sprays, solutions or dusting powders.
  • a pharmaceutical composition may be formulated in unit dosage form (ie in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose).
  • the compounds of the present invention may be provided as a pharmaceutically acceptable salt including, for example, suitable acid addition or base salts thereof.
  • suitable pharmaceutical salts may be found in Berge et al., J Pharm Sci 66:1-19 (1977 ).
  • Salts are formed, for example with strong inorganic acids such as mineral acids (eg sulfuric acid, phosphoric acid or hydrohalic acids), with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted (eg by halogen), such as acetic acid, with saturated or unsaturated dicarboxylic acids (eg oxalic, malonic, succinic, maleic, fumaric, phthalic or tetraphthalic acid), with hydroxycarboxylic acids (eg ascorbic, glycolic, lactic, malic, tartaric or citric acid), with amino acids (eg aspartic or glutamic acid), with benzoic acid, or with organic s
  • the compounds of the present invention may be provided in their various crystalline forms, polymorphic forms and (an)hydrous forms.
  • chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation from the solvents used in the synthetic preparation of such compounds.
  • Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the examples hereinafter. Alternatively, necessary starting materials may be obtainable by analogous procedures to those illustrated which are within the ordinary skill of those skilled in the art. Further, it will be appreciated that during the synthesis of the compounds, in the processes described below, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. Those skilled in the art will readily recognise when such protection is required, and how such protecting groups may be put in place, and later removed. Examples of protecting groups are described in, for example, Protective Groups in Organic Synthesis by Theodora Green (publisher: John Wiley & Sons ).
  • Protecting groups may be removed by any convenient method well known to those skilled in the art as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule.
  • reactants include, for example, groups such as amino, carboxyl or hydroxyl, it may be desirable to protect the group in some of the reactions mentioned herein.
  • the compounds of the present invention may be prepared by, for example, the general synthetic methodologies described in International Patent Publication No WO 2013/156780 .
  • a method of synthesising a compound of the present invention (or a pharmaceutically acceptable salt, solvate or prodrug thereof) wherein the method comprises:
  • the coupling reaction between the compound of formula IV and formula V may take place in the presence of a suitable solvent or solvent mixture.
  • suitable solvents include alcohols, acetonitrile, halogenated solvents, etc.
  • reaction conditions to use in the coupling reaction between the compound of formula IV and formula V.
  • the reaction will be carried out in anhydrous conditions and in the presence of an inert atmosphere, such as argon or nitrogen.
  • the reaction may also be carried out an elevated temperature, such as, for example, within the range of 80 to 180°C for a suitable time period of, for example, 20 minutes to 48 hours.
  • the reaction is carried out under microwave heating, for example, at 80 to 180 °C for 20 minutes to 1.5 hour.
  • the resultant compound can be isolated and purified using techniques well known to those skilled in the art.
  • the method of synthesising a compound of the present invention may further comprise: c) subjecting the compound of formula II to a salt exchange (particularly in situations where the compound is formed as a mixture of different salt forms).
  • the salt exchange may comprise immobilising the compound on a suitable solid support or resin, and eluting the compound with an appropriate acid to yield salt of the compound of formula II.
  • 1 H and 13 C NMR spectra were recorded at 300 K on a Bruker AVANCE III 500 spectrometer ( 1 H at 500 MHz and 13 C NMR at 125 MHz). 1 H and 13 C NMR spectra were referenced to 1 H signals of residual non-deuterated solvents (ortetramethylsilane) and 13 C signals of the deuterated solvents respectively. High resolution mass spectra were recorded on an AB SCIEX TripleTOF ® 5600 mass spectrometer, and ionisation of all samples was carried out using ESI. The purity of compounds was determined by analytical HPLC, and was greater than 95%.
  • Compound 95 was obtained as a brown solid (30 mg, 7%) by-product in the process of synthesising and purifying 1-(4-(6-((4-(4-methyl-2-(methylthio)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one.
  • the kinase reaction was performed with standard assay buffer and Kinase Dilution Buffer and RBER-IRStide substrate. Serial dilutions of 1:3 were prepared for test compounds for 10 concentrations (from 10 ⁇ M to 0.5 nM). The kinase reactions were started by addition of ATP, incubated for 40 min at 37° C and then stopped by adding 10 ⁇ L of ADP Glo reagent. After incubation at room temperature in the dark for 40 min, 20 ⁇ L of kinase detection reagent was added per well and incubated for 40 min. Luminescence was measured using an EnVision Multilabel plate reader (PerkinElmer, Buckinghamshire, UK).
  • the collected pellets were incubated with staining solution (50 ⁇ g/mL PI, 0.1 mg/mL ribonuclease A, 0.05% Triton X-100) at 37 °C for an hour and analysed with Gallios flow cytometer. 1 ⁇ 10 5 of the remaining cells were then used in an apoptotic assay with Annexin V-FITC Apoptosis Detection Kit. The samples were analysed by FACS within one hour of staining. Data were analysed using Kaluza v1.2.
  • MV4-11 cells were treated with compound 60 for 24 h at the concentrations shown. It was found that compound 60 arrested cells in the G1 phase of the cell-cycle in a dose-dependent manner, confirming its inhibitory activity against cellular CDK4/6. Treatment of cancer cells with compounds resulted in apoptosis as represented by the sum of early (annexin-V+/PI-) and late (annexin-V+/PI+) apoptosis. A representative example is shown in Figure 2 .
  • mice healthy male adult Balb/C mice (weighing 20-25 g) or Wistar Rat (weighing 250-350 g) were split into weight matched groups of 3 per group.
  • Compound was administered IV (2 mg/kg for mice, 5 mg/kg for rats) via the tail vein or by oral gavage (20 mg/kg).
  • Blood samples were collected from animals by jugular vein cannula (rats) or under anaesthesia by cardiac puncture (mice) at time zero and at intervals up to 24 h.
  • Harvested blood was centrifuged at 7000 x G for 2 minutes, and the plasma aspirated and frozen at -20°C until analysis. Quantitative analysis of compound in plasma was carried out using LC-MS/MS methods.
  • MV4-11 MDA-MB-453 1 1.099 ⁇ 0.345 >10 2 1.021 ⁇ 0.007 >10 3 0.053 ⁇ 0.003 0.378 ⁇ 0.029 4 0.296 ⁇ 0.287 1.973 ⁇ 0.404 5 0.500 ⁇ 0.247 0.914 ⁇ 0.098 6 2.129 ⁇ 0.969 >10 7 0.606 ⁇ 0.150 3.860 ⁇ 0.220 8 0.750 ⁇ 0.246 3.009 ⁇ 0.705 9 0.591 ⁇ 0.083 3.320 ⁇ 0.576 10 5.372 ⁇ 1.685 >10 11 >10 >10 12 5.294 ⁇ 0.811 >10 13 0.029 ⁇ 0.019 0.703 ⁇ 0.071 14 0.596 ⁇ 0.231 >10 15 0.063 ⁇ 0.026 0.542 ⁇ 0.065 16 0.457 ⁇ 0.122 >10 17 0.649 ⁇ 0.024 1.054 ⁇ 0.203 18 0.418 ⁇ 0.023 0.166 ⁇ 0.117 19

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (13)

  1. Composé de la formule II illustrée ci-dessous :
    Figure imgb0134
     dans lequel :
    R1, R4, R6 et R7 sont sélectionnés chacun indépendamment parmi le groupe composé de H, alkyle, alkyle-R10, aryle, aryle-R10, aralkyle, aralkyle-R11, halogène, NO2, CN, CF3, OH, O-alkyle, COR10, COOR10, O-aryle, O-R10, NH2, NH-alkyle, NH-aryle, N-(alkyle)2, N-(aryle)2, N-(alkyle)(aryle), NH-R10, N-(R10)(R11), -N(alkyle)(R10), N-(aryle)(R10), COOH, CONH2, CONH-alkyle, CONH-aryle, CON-(alkyle)(R10), CON(aryle)(R10, C0NH-R10, CON-(R10)(R11), SO3H, SO2-alkyle, SO2-alkyle-R10, SO2-aryle, SO2-aryle-R10, SO2NH2, SO2NH-R10, SO2N-(R10)(R11), CF3, CO-alkyle, CO-alkyle-R10, CO-aryle, CO-aryle-R10 et
    R12, dans lequel lesdits groupes alkyle, aryle et aralkyle peuvent être optionnellement substitués par un ou plusieurs groupes sélectionnés parmi halogène, CN, OH, O-méthyle, NH2, COOH, CONH2 et CF3 ;
    R2 est un alkyle C1-3 ;
    R3 est H, un alkyle C1-6, CN ou halogène ;
    R5 est sélectionné parmi alkyle, alkyle-R10, aryle, aryle-R10, aralkyle, aralkyle-R11, halogène, NO2, CN, CF3, OH, O-alkyle, COR10, COOR10, O-aryle, O-R10, NH2, NH-alkyle, NH-aryle, N-(alkyle)2, N-(aryle)2, N-(alkyle)(aryle), NH-R10, N-(R10)(R11), -N-(alkyle)(R10), -N(aryle)(R10), SH-alkyle, SH-aryle, S-(alkyle)2, S-(aryle)2, - S(alkyle)(aryle), SH-R10, S-(R10)(R11), S-(alkyle)(R10), S-(aryle)(R10), COOH, CONH2, CONH-alkyle, CONH-aryle, CON-(alkyle)(R10), CON-(aryle)(R10), CONH-R10, CON-(R10)(R11), SO3H, SO2-alkyle, SO2-alkyle-R10, SO2-aryle, SO2-aryle-R10, SO2NH2, SO2NH-R10, SO2N-(R10)(R11), CF3, CO-alkyle, CO-alkyle-R10, CO-aryle, CO-aryle-R10 et
    R12, dans lequel lesdits groupes alkyle, aryle et aralkyle peuvent être optionnellement substitués par un ou plusieurs groupes sélectionnés parmi halogène, CN, OH, O-méthyle, NH2, COOH, CONH2 et CF3 ;
    R10, R11 et R12 sont sélectionnés indépendamment parmi le groupe de groupes se solubilisant dans l'eau composés de : groupes alicycliques monohydroxylés, dihydroxylés et polyhydroxylés, groupes aliphatiques ou aryle dihydroxylés ou polyhydroxylés, groupes hétérocycliques contenant N, O et/ou S substitués par un ou plusieurs groupes hydroxyle ou amino, groupes aliphatiques et aryle comprenant un ou plusieurs groupes carboxamide, sulfoxyde, sulfone ou sulfonamide, et de groupes alkylcarbonyle halogénés, et COOH, SO3H, OSO3H, PO3H2 et OPO3H2, excepté que lorsque R5 et/ou R6 est/sont R12, dans quel cas R12 est sélectionné parmi le groupe de groupes se solubilisant dans l'eau composés de :
    groupes alicycliques monohydroxylés, dihydroxylés et polyhydroxylés, groupes aliphatiques ou aryle dihydroxylés ou polyhydroxylés, groupes hétérocycliques contenant N, O et/ou S substitués par un ou plusieurs groupes hydroxyle ou amino, groupes aliphatiques et aryle comprenant un ou plusieurs groupes carboxamide, sulfoxyde, sulfone ou sulfonamide, et de groupes alkylcarbonyle halogénés, et COOH, SO3H, OSO3H, PO3H2 et OPO3H2 et des groupes suivants :
    Figure imgb0135
    Figure imgb0136
    Figure imgb0137
    ou un sel ou un solvate pharmaceutiquement acceptable de ceux-ci.
  2. Composé selon la revendication 1, dans lequel R5 est R12.
  3. Composé selon la revendication 1, dans lequel :
    R1, R4, R6 et R7 sont sélectionnés chacun indépendamment parmi le groupe composé de H, alkyle, aryle, aralkyle, halogène, NO2, CN, CF3, OH, O-alkyle, O-aryle, NH2, NH-alkyle, NH-aryle, N-(alkyle)2, N-(aryle)2, N-(alkyle)(aryle), NH-R10, N-(R10)(R11),-N(alkyle)(R10) et N-(aryle)(R10), COOH, CONH2, CONH-alkyle, CONH-aryle, SO3H, SO2-alkyle, SO2-aryle, SO2NH2, CF3, CO-alkyle et CO-aryle, dans lequel lesdits groupes alkyle, aryle et aralkyle peuvent être optionnellement substitués par un ou plusieurs groupes sélectionnés parmi halogène, CN, OH, O-méthyle, NH2, COOH, CONH2 et CF3 ;
    R2 est un alkyle C1-3 ;
    R3 est H, un alkyle C1-6, CN ou halogène ; et
    R5 est R12,
    ou un sel ou un solvate pharmaceutiquement acceptable de celui-ci.
  4. Composé selon l'une quelconque des revendications 1 à 3, dans lequel R1 est H, un alkyle C1-6, aryle, NH-alkyle C1-6, N(alkyle C1-6)2, NH-aryle ou N-(alkyle C1-6)(aryle).
  5. Composé selon l'une quelconque des revendications 1 à 3, dans lequel R1 est NH-CH3, N(CH3)2, NH(C5H9), NH(C5H9)2, NH-aryle ou N-(alkyle)(aryle).
  6. Composé selon l'une quelconque des revendications 1 à 5, dans lequel R3 est un alkyle C1-3, CN ou un halogène.
  7. Composé selon l'une quelconque des revendications 1 à 6, dans lequel R4 est H, un O-alkyle C1-6 ou un halogène.
  8. Composé selon la revendication 2, dans lequel R6 est H.
  9. Composé selon la revendication 2 ou 8, dans lequel R12 est sélectionné parmi les suivants :
    Figure imgb0138
  10. Composé selon l'une quelconque des revendications 1 à 9, dans lequel R7 est H.
  11. Composé selon la revendication 3, où le composé est de la :
    5-(5-fluoro-2-((5-(4-méthylpipérazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-N,N,4-triméthylthiazol-2-amine, N-cyclopentyl-5-(2-((5-(4-éthylpipérazin-1-yl)méthyl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-méthylthiazol-2-amine ou N-cyclopentyl-5-(2-((5-(4-éthylpipérazin-1-yl)méthyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-méthylthiazol-2-amine.
  12. Composé selon l'une quelconque des revendications 1 à 11 ou un sel ou un solvate pharmaceutiquement acceptable de celui-ci, pour une utilisation dans le traitement d'un cancer ou d'une autre maladie ou condition proliférative cellulaire, où la maladie ou condition proliférative cellulaire à traiter est sélectionnée parmi celles qui se caractérisent par une surexpression de CDK4 et/ou de CDK6.
  13. Composition pharmaceutique ou médicament comprenant le composé selon l'une quelconque des revendications 1 à 11 et un véhicule, un diluant et/ou un excipient pharmaceutiquement acceptables.
EP16831959.8A 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques Active EP3331880B3 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21196611.4A EP3957637B1 (fr) 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidine-2-amine utilisés comme composés thérapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015903106A AU2015903106A0 (en) 2015-08-04 Novel kinase inhibitors ii
PCT/AU2016/000269 WO2017020065A1 (fr) 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP21196611.4A Division-Into EP3957637B1 (fr) 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidine-2-amine utilisés comme composés thérapeutiques
EP21196611.4A Division EP3957637B1 (fr) 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidine-2-amine utilisés comme composés thérapeutiques

Publications (4)

Publication Number Publication Date
EP3331880A1 EP3331880A1 (fr) 2018-06-13
EP3331880A4 EP3331880A4 (fr) 2019-05-01
EP3331880B1 EP3331880B1 (fr) 2021-12-01
EP3331880B3 true EP3331880B3 (fr) 2023-01-11

Family

ID=57942114

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16831959.8A Active EP3331880B3 (fr) 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques
EP21196611.4A Active EP3957637B1 (fr) 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidine-2-amine utilisés comme composés thérapeutiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP21196611.4A Active EP3957637B1 (fr) 2015-08-04 2016-08-04 Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidine-2-amine utilisés comme composés thérapeutiques

Country Status (7)

Country Link
US (4) USRE49850E1 (fr)
EP (2) EP3331880B3 (fr)
JP (1) JP6842458B2 (fr)
CN (2) CN108349964B (fr)
AU (1) AU2016302384B2 (fr)
CA (1) CA2994023A1 (fr)
WO (1) WO2017020065A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349964B (zh) * 2015-08-04 2021-06-01 常州千红生化制药股份有限公司 N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
CA3051604A1 (fr) 2017-02-01 2018-08-09 Aucentra Therapeutics Pty Ltd Derives de n-cycloalkyl/heterocycloalkyle-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine en tant qu'agents therapeutiques
CN110016023B (zh) * 2018-01-08 2020-05-08 新发药业有限公司 一种帕博西尼的简便制备方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN111039941B (zh) * 2018-10-12 2023-03-21 上海医药集团股份有限公司 一种含氮杂环化合物、其制备方法及应用
EP3889156A4 (fr) 2018-11-30 2022-07-20 Shanghai Pharmaceuticals Holding Co., Ltd. Composé hétérocyclique contenant de l'azote, composition à base de celui-ci, procédé de préparation correspondant et utilisation associée
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2021003517A1 (fr) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Dérivés de 4-(imidazo [l, 2-a] pyridine-3-yl)-n-(pyridinyl) pyrimidine-2-amine en tant qu'agents thérapeutiques
JOP20220087A1 (ar) 2019-10-11 2023-01-30 Incyte Corp أمينات ثنائية الحلقة كمثبطات لـ cdk2
AU2020367204A1 (en) * 2019-10-15 2022-04-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-N-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
US20230181580A1 (en) * 2020-05-06 2023-06-15 Aucentra Therapeutics Pty Ltd Treatment of proliferative diseases of the cns
CN111777604B (zh) * 2020-07-17 2021-12-21 常州大学 一种作为cdk2抑制剂的2-胺基噻唑嘧啶的合成方法
CN112239466B (zh) * 2020-11-10 2021-06-08 常州千红生化制药股份有限公司 选择性cdk4/6抑制剂的琥珀酸盐及其晶型
WO2022113003A1 (fr) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
WO2022149057A1 (fr) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN114028400B (zh) * 2021-12-01 2023-10-31 常州英诺升康生物医药科技有限公司 一种含有细胞周期蛋白激酶抑制剂的药物组合物及其制备方法
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023173170A1 (fr) * 2022-03-17 2023-09-21 Aucentra Therapeutics Pty Ltd Utilisation de dérivés de 4-thiazol-n-(pyridin-2-yl)pyrimidin-2-amine dans des polythérapies pour le cancer
WO2023173172A1 (fr) * 2022-03-17 2023-09-21 Aucentra Therapeutics Pty Ltd Utilisation de 5-(2-((5-(4-(diméthylamino)pipéridin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-n,4-diméthylthiazol-2-amine dans des polythérapies pour le cancer
CN115160307A (zh) * 2022-08-02 2022-10-11 常州英诺升康生物医药科技有限公司 一种ls010杂质化合物b及其制备工艺和应用
CN115636826A (zh) * 2022-10-31 2023-01-24 常州英诺升康生物医药科技有限公司 一种cdk抑制剂的制备方法
CN116693522B (zh) * 2023-08-04 2023-10-31 苏州共康医药科技有限公司 Cdk4/6抑制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ATE482946T1 (de) 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
HUP0300382A3 (en) * 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
EP1648887A1 (fr) * 2003-07-30 2006-04-26 Cyclacel Limited Derives de pyridinylamino-pyrimidine utiles comme inhibiteurs de la proteine kinase
GB0317842D0 (en) * 2003-07-30 2003-09-03 Cyclacel Ltd Compound
WO2005042525A1 (fr) * 2003-10-21 2005-05-12 Cyclacel Limited Composes de pyrimidin-4-yl-3, 4-thione et leur utilisation a des fins therapeutiques
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
EP1951307A2 (fr) 2005-11-11 2008-08-06 Cyclacel Limited Combinaison d'un inhibiteur cdk avec un inhibiteur d'hdac
KR100981109B1 (ko) * 2008-10-27 2010-09-08 한국과학기술원 고체산화물 연료전지의 연료 개질을 위한 통합반응기
EP2406234A1 (fr) * 2009-03-12 2012-01-18 GlaxoSmithKline LLC Inhibiteurs de thiazole sulfonamide et oxazole sulfonamide kinases
GB201206908D0 (en) 2012-04-19 2012-06-06 Cancer Rec Tech Ltd Therapeutic compounds
WO2014176210A1 (fr) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole inhibiteurs de tyrosine kinase splénique
CN108349964B (zh) * 2015-08-04 2021-06-01 常州千红生化制药股份有限公司 N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物

Also Published As

Publication number Publication date
CA2994023A1 (fr) 2017-02-02
JP6842458B2 (ja) 2021-03-17
USRE49850E1 (en) 2024-02-27
US20180222900A1 (en) 2018-08-09
US20220267315A1 (en) 2022-08-25
EP3957637A1 (fr) 2022-02-23
EP3331880A1 (fr) 2018-06-13
WO2017020065A1 (fr) 2017-02-09
US10479785B2 (en) 2019-11-19
EP3957637B1 (fr) 2023-06-28
AU2016302384B2 (en) 2020-07-16
CN108349964B (zh) 2021-06-01
AU2016302384A1 (en) 2018-03-08
CN113336746A (zh) 2021-09-03
JP2018527334A (ja) 2018-09-20
US11970491B2 (en) 2024-04-30
US20200283431A1 (en) 2020-09-10
EP3331880A4 (fr) 2019-05-01
EP3331880B1 (fr) 2021-12-01
CN108349964A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
EP3331880B3 (fr) Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques
AU2018214431B2 (en) Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
IL198243A (en) Ammonia in 2- (pyridine-2-ylmino) -pyrido [3,2- d] pyrimidine-7-helpless in the preparation of a drug to treat a condition or disorder caused by abnormal cell proliferation
CN115666561A (zh) Cns的增殖性疾病的治疗
US20230092876A1 (en) 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
US20240158391A1 (en) Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
US20220259203A1 (en) Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents
WO2023173170A1 (fr) Utilisation de dérivés de 4-thiazol-n-(pyridin-2-yl)pyrimidin-2-amine dans des polythérapies pour le cancer
US20230339889A1 (en) Derivatives of 2-oxo-n-(4-(pyrimidin-4-yloxy/thio)phenyl)-1,2-dihydropyridine-3-carboxamide for use as protein kinase inhibitors for therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190402

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/506 20060101ALI20190327BHEP

Ipc: C07D 417/14 20060101AFI20190327BHEP

Ipc: A61K 31/427 20060101ALI20190327BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AUCENTRA THERAPEUTICS PTY LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200429

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210218

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20210514

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AUCENTRA THERAPEUTICS PTY LTD

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1451663

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016066915

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20211201

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1451663

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220301

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220301

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220302

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220401

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

REG Reference to a national code

Ref country code: DE

Ref legal event code: R055

Ref document number: 602016066915

Country of ref document: DE

PLCP Request for limitation filed

Free format text: ORIGINAL CODE: EPIDOSNLIM1

PLCQ Request for limitation of patent found admissible

Free format text: ORIGINAL CODE: 0009231

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016066915

Country of ref document: DE

LIM1 Request for limitation found admissible

Free format text: SEQUENCE NO: 1; FILED DURING OPPOSITION PERIOD

Filing date: 20220818

Effective date: 20220818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220401

PLCR Communication despatched that request for limitation of patent was allowed

Free format text: ORIGINAL CODE: 0009245

REG Reference to a national code

Ref country code: DE

Ref legal event code: R056

Ref document number: 602016066915

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

26N No opposition filed

Effective date: 20220902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

PLCN Payment of fee for limitation of patent

Free format text: ORIGINAL CODE: EPIDOSNRAL3

PUAM (expected) publication of b3 document

Free format text: ORIGINAL CODE: 0009410

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN LIMITED

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220804

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230705

Year of fee payment: 8

Ref country code: CH

Payment date: 20230902

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230809

Year of fee payment: 8

Ref country code: FR

Payment date: 20230811

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211201